History

2016

  • Metformin DR Phase 2b study confirms gut-based mechanism and doses for Phase 3 development | November 2016

2015

  • Series E financing | October 2015
  • Series D financing | February 2015

2014

  • Data demonstrating low systemic exposure with Metformin DR in type 2 diabetes subjects with renal impairment | July 2014

2013

  • Metformin DR formulation patent application filed | January 2013
  • Metformin DR PK data confirm lower exposure relative to currently available formulations | February 2013
  • Series C financing | February 2013
  • Metformin DR fixed-dose combination patent application filed | July 2013
  • NaZura BioHealth formed to develop weight loss supplement based on GSM | August 2013
  • Metformin DR Phase 2 study supports gut-based mechanism and defines doses for further development | October 2013

2012

  • Data demonstrating low systemic exposure with Metformin DR in healthy subjects | March 2012
  • Additional Metformin DR patent application filed | May 2012
  • Data supporting once-daily dosing of Metformin DR | June 2012
  • Series B financing extension | September 2012
  • Metformin DR data showed dissociation between metformin plasma exposure and glucose lowering effects in type 2 diabetes subjects | November 2012

2011

  • Initial Metformin DR Patent application filed | January 2011
  • Series B financing | March 2011

2010

  • Elcelyx management team announced | March 2010
  • Series A financing | April 2010

2009

  • Elcelyx incorporated | February 2009
  • Gut Sensory Modulation (GSM) patent application filed | April 2009